Podcast Episodes

Back to Search
368: New stakes in the vaccine dispute and a boost for biotech

Labor Day is in the rearview mirror, and that means Adam, Elaine, and Allison are all back to work. They take the pulse of the biotech market and dis…

1 year, 1 month ago

Short Long
View Episode
367: The ouster of CDC's director, biotech venture firm rankings

We bring on Washington correspondent Chelsea Cirruzzo to explain the ouster of CDC Cirector Susan Monarez and the resignations of other top officials…

1 year, 1 month ago

Short Long
View Episode
366: Viking’s obesity flop, ‘pharma to table’ drug sales

On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The ga…

1 year, 2 months ago

Short Long
View Episode
365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to …

1 year, 2 months ago

Short Long
View Episode
364: Closing a zombie biotech, and Lilly's disappointing obesity readout

We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us …

1 year, 2 months ago

Short Long
View Episode
363: What Vinay Prasad’s ouster means for biotech and the FDA

This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s bi…

1 year, 2 months ago

Short Long
View Episode
362: A mother’s perspective on Sarepta’s gene therapy halt

We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys fro…

1 year, 2 months ago

Short Long
View Episode
361: Inside an FDA drug rejection, and layoffs at Sarepta

Just how many employees is Sarepta Therapeutics laying off? And why did the Food and Drug Administration reject Ultragenyx’s rare disease drug over m…

1 year, 3 months ago

Short Long
View Episode
360: NIH grant cuts, FDA transparency questions and biotech M&A

On this week’s episode of the Readout LOUD: A closer look at the NIH’s grant-cutting legal playbook, a not-so-transparent transparency push by the FD…

1 year, 3 months ago

Short Long
View Episode
359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

We invite STAT’s senior writer for infectious diseases, Helen Branswell, and Washington correspondent Chelsea Cirruzzo on to the podcast to discuss t…

1 year, 3 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us